List view / Grid view
13 January 2016 | By Victoria White
Results from a study demonstrate that Roche’s cardiac troponin T-high-sensitivity test shortens the time to diagnose heart attack to one hour from three hours or more...
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
7 January 2016 | By Nicholas Jackson
PROGNOSIS study published in the New England Journal of Medicine reveals that an innovative Roche blood test can be used as a predictive tool for preeclampsia...
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
14 December 2015 | By Victoria White
Alecensa (alectinib) is approved for patients whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib)...
1 December 2015 | By Victoria White
The novel, oral small molecule inhibitor of VAP-1 is a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases...
25 November 2015 | By Victoria White
The approval is based on data that showed Cotellic plus Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live for more than a year without their disease worsening...
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
13 November 2015 | By Victoria White
Tagrisso (AZD9291) is the only approved medicine indicated for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer...
13 November 2015 | By Victoria White
Roche plans to restructure its manufacturing network for small molecules to address current underutilisation as a result of its evolving portfolio...
11 November 2015 | By Victoria White
The approval is for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma...
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
9 October 2015 | By Victoria White
Roche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
6 October 2015 | By Victoria White
Results from a Phase III study show that Cotellic plus Zelboraf helped people with advanced melanoma live significantly longer compared to Zelboraf alone...
